Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5276294
Max Phase: Preclinical
Molecular Formula: C20H23N5O
Molecular Weight: 349.44
Associated Items:
ID: ALA5276294
Max Phase: Preclinical
Molecular Formula: C20H23N5O
Molecular Weight: 349.44
Associated Items:
Canonical SMILES: Nc1cccc(-c2cn(CC(O)CN3CCc4ccccc4C3)nn2)c1
Standard InChI: InChI=1S/C20H23N5O/c21-18-7-3-6-16(10-18)20-14-25(23-22-20)13-19(26)12-24-9-8-15-4-1-2-5-17(15)11-24/h1-7,10,14,19,26H,8-9,11-13,21H2
Standard InChI Key: VHHLKQFSVSDZNK-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 349.44 | Molecular Weight (Monoisotopic): 349.1903 | AlogP: 1.95 | #Rotatable Bonds: 5 |
Polar Surface Area: 80.20 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 8.39 | CX LogP: 2.38 | CX LogD: 1.34 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.69 | Np Likeness Score: -1.40 |
1. Fu S, Zheng Q, Zhang D, Lin C, Ouyang L, Zhang J, Chen L.. (2022) Medicinal chemistry strategies targeting PRMT5 for cancer therapy., 244 [PMID:36274274] [10.1016/j.ejmech.2022.114842] |
Source(1):